{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T18:34:59Z","timestamp":1759775699785},"reference-count":14,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.ejca.2012.11.015","type":"journal-article","created":{"date-parts":[[2012,12,25]],"date-time":"2012-12-25T15:45:16Z","timestamp":1356450316000},"page":"904-910","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: A randomised phase II trial from the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA)"],"prefix":"10.1016","volume":"49","clinical-trial-number":[{"clinical-trial-number":"nct00136591","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Vincent","family":"Ribrag","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herv\u00e9","family":"Tilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Casasnovas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Bosly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reda","family":"Bouabdallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Delarue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Boue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Bron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Feugier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Haioun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Firtz","family":"Offner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Coiffier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2012.11.015_b0005","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the international lymphoma study group classification of non-Hodgkin\u2019s lymphoma. The non-Hodgkin\u2019s lymphoma classification project","volume":"89","author":"Anon","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2012.11.015_b0010","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1053\/j.seminoncol.2004.02.007","article-title":"Advances in follicular lymphoma","volume":"31","author":"Archuleta","year":"2004","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejca.2012.11.015_b0015","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2141.2006.06378.x","article-title":"Current management of follicular lymphomas","volume":"136","author":"Hiddemann","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2012.11.015_b0020","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2012.11.015_b0025","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1200\/JCO.2005.03.1674","article-title":"New treatment options have changed the survival of patients with follicular lymphoma","volume":"23","author":"Fisher","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.11.015_b0030","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1200\/JCO.2005.04.503","article-title":"Improved survival of follicular lymphoma patients in the United States","volume":"23","author":"Swenson","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.11.015_b0035","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1200\/JCO.2005.03.3696","article-title":"Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center","volume":"24","author":"Liu","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.11.015_b0040","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.11.015_b0045","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma","volume":"23","author":"O\u2019Connor","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.11.015_b0050","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1182\/blood-2009-08-233155","article-title":"Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma","volume":"115","author":"Di Bella","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2012.11.015_b0055","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1365-2141.2009.07775.x","article-title":"Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma","volume":"146","author":"Gerecitano","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2012.11.015_b0060","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1158\/1078-0432.CCR-08-2647","article-title":"Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes","volume":"16","author":"O\u2019Connor","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2012.11.015_b0065","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2005.04.6789","article-title":"Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity","volume":"24","author":"Strauss","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.11.015_b0070","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an International Workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804912009112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804912009112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,19]],"date-time":"2020-07-19T11:22:26Z","timestamp":1595157746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804912009112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0959804912009112"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2012.11.015","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}